SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher full-year revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is driving the rally and renewed confidence in its commercial growth. Traders are broadly bullish, with short-squeeze chatter and anticipation of lung-cancer data adding to the excitement, though the squeeze talk remains speculative.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reports of improving Reddit user growth, including a positive read on U.S. user trends, sparked bullish discussion and a rebound. Skeptics remain focused on uncertainty around Googles AI-data licensing deal, insider selling, and the stocks persistent weakness.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles new change-of-control severance policy has fueled speculation about a potential buyout or strategic investment, though traders note the filing is not evidence of an active deal. The chatter is tempered by frustration over missing shipment and launch updates, with some viewing execution delays as the more important issue.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for a U.S. Army prototype program developing next-generation 10 kV silicon-carbide semiconductors is the main catalyst. Bulls view the award as technology and domestic-manufacturing validation with potential defense and infrastructure applications, while skeptics note the value was not disclosed and the prototype may not produce meaningful near-term revenue, fueling sell-the-news debate after a sharp move.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA changes allowing Fannie Mae and Freddie Mac to use VantageScore alongside FICO are fueling concern that competition could erode Fair Isaacs long-standing mortgage credit-scoring dominance. Traders are divided between viewing the sharp selloff as an overreaction and expecting further pressure as lenders gain a cheaper alternative.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reports that Lundbeck is interested in acquiring Xeris have sparked takeover speculation alongside discussion of a sharp increase in trading volume. Traders are debating potential deal value, while some attribute the broader interest to Xeriss growth prospects and XP-8121 pipeline; no acquisition has been confirmed.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Attention centers on Evernorths SPAC merger and Nasdaq listing progress, alongside its planned XRP treasury strategy. Traders are bullish on the potential XRP-linked exposure and warrants, while others question the valuation, execution, and volatility.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnival is rallying after quarterly results topped expectations, with traders highlighting strong cruise demand, record forward bookings and improved full-year guidance. Bulls view the results as evidence of resilient business momentum, while skeptics point to elevated fuel costs and softer near-term earnings guidance as risks.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

A sharp selloff in long-term Treasuries as yields reach multi-year highs is driving discussion, with traders citing persistent inflation, possible Fed tightening, and government debt concerns. Many expect further weakness in TLT if yields keep rising, while others see the decline as oversold and are accumulating in anticipation of a rebound.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Jobys Texas eIPP flights and autonomous cross-country flight have drawn attention, with bullish traders pointing to FAA certification progress and future commercial potential. The conversation is also dominated by the stocks steep decline and concerns about cash burn, dilution and insider selling, while long-term holders argue that Toyotas backing and development milestones support the case for patience.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS a $40 Billion buyout is an absolute steal for Big Pharma.

When you model a continuous Treat-to-Progression (TTP) lifecycle that replaces million-dollar surgeries and cannibalises Onureg, our AML monopoly alone scales to $7.28 Billion in peak annual sales.

At a $40B buyout, Big Pharma is securing that leukemia engine at a bargain 5.5x Price-to-Sales multiple.

Here is what the general boards completely miss: A $40B acquisition means they are getting our universal WT1 multi-cancer platform—valued at an additional $12.0 Billion across 20+ solid tumor indications—completely for free.

Slatelabs

SoYeon

NorvaK

Nobody Special

Saif Kareem

ming yu

Tony M

bikechain

Anthony Sassin

Zoran

Amarante Scott

Jonathan

Dave

Andy L.

JALIB

Allan Kristensen

Janulf

Juhana Tikkanen

Sandra McDaniel

Sterg

Anon

Kris Kotsay

Wayne

Daniela Todorova

uhguy85

Stephen

StockTwits for iOS

SELLAS Life Sciences Group Inc

 a $40 Billion buyout is an absolute steal for Big Pharma.

When you model a continuous Treat-to-Progression (TTP) lifecycle that replaces million-dollar surgeries and cannibalises Onureg, our AML monopoly alone scales to $7.28 Billion in peak annual sales.

At a $40B buyout, Big Pharma is securing that leukemia engine at a bargain 5.5x Price-to-Sales multiple.

Here is what the general boards completely miss: A $40B acquisition means they are getting our universal WT1 multi-cancer platform—valued at an additional $12.0 Billion across 20+ solid tumor indications—completely for free.

Duncan Teo

@Duncan74 so what would that bring the share price too?

 so what would that bring the share price too?